Abstract: The present invention provides devices, systems, and methods for control of ventricular assist devices. The invention includes an implantable controller that is operatively programmed to direct physiological flow through a ventricular assist device that is substantially synchronized to the cardiac cycle of the subject. The implantable controller is also communicatively connected to an external control unit, such that the implantable controller can transmit data to the external control unit, and instructions can be sent from the external control unit to the implantable controller.

Abstract: A ventricular assist device (VAD) system includes one or more external subsystems including an amplifier energizing a drive loop with alternating current, and a Tx resonator inductively coupled to the drive loop. An implanted subsystem includes a VAD, an Rx resonator that forms a magnetically coupled resonator with the Tx resonator, and a load loop for providing power to the VAD that is inductively coupled to the Rx resonator. A sensor monitors the drive loop and a controller uses the sensor data to adjust a system parameter to optimize energy transfer performance. Distributing a plurality of the external subsystems throughout a defined space provides a patient with freedom of movement within the defined space.

Abstract: A ventricular assist device (VAD) system includes one or more external subsystems including an amplifier energizing a drive loop with alternating current, and a Tx resonator inductively coupled to the drive loop. An implanted subsystem includes a VAD, an Rx resonator that forms a magnetically coupled resonator with the Tx resonator, and a load loop for providing power to the VAD that is inductively coupled to the Rx resonator. A sensor monitors the drive loop and a controller uses the sensor data to adjust a system parameter to optimize energy transfer performance. Distributing a plurality of the external subsystems throughout a defined space provides a patient with freedom of movement within the defined space.

Abstract: Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient.